Nephrology Forum

Kidney International (1993) 43, 955–965; doi:10.1038/ki.1993.134

Prostatic cancer

Presentation of this Forum is made possible by grants from Merck Sharp & Dohme International; Amgen, Incorporated; Dialysis Clinic, Incorporated; Parke-Davis, Incorporated; Marion Merrell Dow, Incorporated; and Sandoz, Incorporated.

Carl Olsson Principal discussant:1

1Columbia-Presbyterian Medical Center, New York, New York, USA

Correspondence: Dr C Olsson Chairman, Department of Urology, Columbia-Presbyterian Medical Center, The Allen Pavillion, 5141 Broadway, Room 3-005, New York, New York 10034, USA

Top

References

  1. Boring CC, Squires TS, Tong T: Cancer statistics. Cancer 41:19, 1991
  2. Goluboff E, Olsson CA: Urologists on a tightrope: coping with a changing economy. J Urol, in press
  3. Viola MV, Fromowitz F, Oravez S, Deb S, Finkel G, Lundy J, Hand P, Thor A, Schlom J: Expression of ras oncogene p21 in prostate cancer. N Engl J Med 314:133–137, 1986 | PubMed | ChemPort |
  4. Thompson TC, Southgate J, Kitchener G, Land H: Multistage carcinogenesis induced by ras and myc oncogenes in a reconstituted organ. Cell 56:917, 1989 | Article | PubMed | ISI | ChemPort |
  5. Zhau HE, Wan D, Chung LK, Wei L, Hsieh JT, Ro J, Chung LWK: Expression of the HER-2/neu proto-oncogene in human prostate cancer (abstract). J Urol 145:348A, 1991
  6. Isaacs WB, Ewing CM, Epstein JI, Carter BS: Suppression of human prostate carcinoma cell growth by p53 in vitro and analysis of p53 mutations in vivo. J Urol 145:349A, 1991
  7. Petros JA, Dowton SB, Catalona WJ: Investigation of retinoblastoma transcripts in primary prostatic adenocarcinoma (abstract). J Urol 145:293A, 1991
  8. Yatani R, Chigusa K, Akazaki K, Stemmerman GN, Welsh RA, Correa P: Geographic pathology of latent prostatic carcinoma. Int J Cancer 29:611–616, 1982 | PubMed |
  9. Waterhouse J, Shanmugaratnam R, Muir C, Powell J: Cancer incidence in five continents, in Cancer Incidence, Lyon, France, IARC, no 42, vol 6, 1982
  10. Levine RL, Wilchinsky M: Adenocarcinoma of the prostate: a comparison of disease in blacks versus whites. J Urol 121:761, 1979
  11. Gittes RF: Carcinoma of the prostate. N Engl J Med 324:236, 1991 | PubMed | ISI | ChemPort |
  12. Steinberg GD, Carter BS, Beaty TL, Childs B, Walsh PC: The familial aggregation of prostate cancer: a case control study (abstract). J Urol 143:313A, 1990
  13. Carter BS, Steinberg GD, Beaty TH, Walsh PC: Evidence for mendelian inheritance in the pathogenesis of prostate cancer (abstract). J Urol 145:213A, 1991
  14. Ragde H, Aldape HC, Bagley CM: Ultrasound guided prostate biopsy; Biopsy gun superior to aspiration. Urology 32:503, 1988 | Article | PubMed | ISI | ChemPort |
  15. Hodge K, McNeal JE, Terris MK, Stamey TA: Random systematic versus directed ultrasound guided transrectal biopsies of the prostate. J Urol 141:71, 1989
  16. Torp-Pederson ST, Lee F: Transrectal biopsy of the prostate guided by transrectal ultrasound. Urol Clin North Am 16:703, 1989
  17. Chodak GW, Keller P, Schoenberg HW: Assessment of screening for prostate cancer using digital rectal examination. J Urol 141:1136, 1989
  18. Wang MC, Valenzuela LA, Murphy GP, Chu TM: Purification of a human prostate specific antigen. Invest Urol 17:159, 1979 | PubMed | ISI | ChemPort |
  19. Nadji M, Tabei SZ, Castro A, Chu TM, Murphy GP, Wang MC, Morales AR: Prostate-specific antigen: an immunohistologic marker for prostatic neoplasms. Cancer 48:1229–1232, 1981 | PubMed | ISI | ChemPort |
  20. Killian CS, Emrich LJ, Vargas FP, Yang N, Wang MC, Priore RL, Murphy GP, Chu TM: Relative reliability of five serially measured markers for prognosis of progression in prostate cancer. J Natl Cancer Inst 76:179–185, 1986
  21. Stamey TA, Yang N, Hay AR, McNeal JE, Freiha FS, Redwine E: Prostate-specific antigen as a serum marker for adenocarcinoma of the prostate. N Engl J Med 317:909–916, 1987 | PubMed | ISI | ChemPort |
  22. Hudson MA, Bahnson RR, Catalona WJ: Clinical use of prostate specific antigen in patients with prostate cancer. J Urol 142:1011, 1989
  23. Benson MC, Whang IS, Olsson CA, McMahon DJ, Cooner WH: The use of prostate specific antigen density to enhance the predictive value of intermediate levels of serum PSA. J Urol 147:817–821, 1992 | PubMed | ChemPort |
  24. Carter HB, Andros R, Metter EJ, Fozard JL, Chan DW, Walsh PC: Early detection of prostate cancer using serial PSA measurements (abstract). J Urol 145:382A, 1991
  25. Catalona WJ, Smith DS, Ratliff TL, Dodds KM, Coplen DE, Yuan JJ, Petros JA, Andriole GL: Measurement of prostate-specific antigen in serum as a screening test for prostate cancer. N Engl J Med 324:1156–1161, 1991 | PubMed | ISI | ChemPort |
  26. Lange PH, Brawer MK: Serum prostate-specific antigen; its use in diagnosis and management of prostate cancer. Urology 33:13, 1989
  27. Cooner WH, Mosley BR, Rutherford CL Jr, Beard JH, Pond HS, Bass RB Jr, Terry WJ: Clinical application of transrectal ultrasonography and prostate specific antigen in the search for prostate cancer. J Urol 139:758–761, 1988
  28. Lee F, Littrup PJ, Torp-Pedersen ST, Mettlin C, McHugh TA, Gray JM, Kumasaka GH, McLeary RD: Prostate cancer: comparison of transrectal US and digital rectal examination for screening. Radiology 168:389–394, 1988
  29. Lee F, Torp-Pedersen S, Littrup PJ, McLeary RD, McHugh TA, Smid AP, Stella PJ, Borlaza GS: Hypoechoic lesions of the prostate: clinical relevance of tumor size, digital rectal examination and prostate-specific antigen. Radiology 170:29–32, 1989
  30. Chodak GW: Screening for prostate cancer; role of ultrasonography. Urol Clin North Am 16:657, 1989
  31. Chodak GW, Schoenberg HW: Progress and problems in screening for carcinoma of the prostate. World J Surg 13:60, 1989
  32. McNeal JE, Redwine EA, Freiha FS, Stamey TA: Zonal distribution of prostatic adenocarcinoma: correlation with histologic pattern and direction of spread. Am J Surg Pathol 12:897, 1988 | PubMed | ChemPort |
  33. Villers A, McNeal JE, Redwine E, Freiha FS, Stamey TA: The role of perineural space invasion in the local spread of prostate adenocarcinoma. J Urol 142:763–768, 1989 | PubMed | ISI | ChemPort |
  34. Babayan RK, White RD, Austen G Jr, Krane RJ, Feldman M, Olsson CA: Benefits and complications of staging pelvic lymph node dissection in prostatic adenocarcinoma. Prostate 1:345–349, 1980
  35. Jewett HJ: The present status of radical prostatectomy for stages A and B prostatic cancer. Urol Clin North Am 2:105, 1975
  36. Paulson DE, Uro-Oncology Research Group: Impact of current staging procedures in assessing disease extent of prostatic carcinoma. J Urol 121:300, 1979
  37. Ebert T, Schmitz-Drager BJ, Burrig KF, Miller S, Pauli N, Kahn T, Ackermann R: Accuracy of imaging modalities in staging the local extent of prostate cancer. Urol Clin North Am 18:453–457, 1991
  38. Andriole GL, Kavoussi LR, Torrence RJ, Lepor H, Catalona WJ: Transrectal ultrasonography in the diagnosis and staging of carcinoma of the prostate. J Urol 140:758–760, 1988
  39. Salo JO, Kivisaari L, Rannikko S, Lehtonen T: Computerized tomography and transrectal ultrasound in the assessment of local extension of prostatic cancer before radical retropubic prostatectomy. J Urol 137:435–438, 1987
  40. Hernandez AD, Smith JA: Transrectal ultrasonography for the early detection and staging of prostate cancer. Urol Clin North Am 17:745, 1990
  41. Emory TH, Reinke DB, Hill AL, Lange PH: Use of CT to reduce understaging in prostate cancer: comparison with conventional staging techniques. Am J Roentgenol 141:351–354, 1983
  42. Golimbu M, Morales P, Al-Askari S, Shulman Y: CAT scanning in staging of prostatic cancer. Urology 18:305–308, 1981
  43. Biondetti PR, Lee JK, Ling D, Catalona WJ: Clinical stage B prostate carcinoma: staging with MR imaging. Radiology 162:325–329, 1987
  44. Mukamel E, Hannah J, Barbaric Z, deKernion JB: The value of computerized tomography scan and magnetic resonance imaging in staging prostatic carcinoma: comparison with the clinical and histological staging. J Urol 136:1231–1233, 1986
  45. Scardino PT, Shinohara K, Wheeler TM, Carter SS: Staging of prostatic cancer. Value of ultrasonography. Urol Clin North Am 16:713–734, 1989
  46. Smith MJV: The lymphatics of the prostate. Invest Urol 3:439, 1966
  47. Sawczuk IS, deVere White R, Gold RP, Olsson CA: Sensitivity of computed tomography in the evaluation of pelvic lymph node metastases from carcinoma of the bladder and prostate. Urology 21:81, 1983
  48. Hricak H, Dooms GC, Jeffrey RB, Avallone A, Jacobs D, Benton WK, Narayan P, Tanagho EA: Prostatic carcinoma: Staging by clinical assessment, CT and MR imaging. Radiology 162:331–336, 1987
  49. Wajsman Z, Gamarra M, Park JJ, Beckley S, Pontes JE: Transabdominal fine needle aspiration of retroperitoneal lymph nodes in staging of genitourinary tract cancer (correlation with lymphography and lymph node dissection findings). J Urol 128:1238–1240, 1982
  50. Winfield HN, Donovan JF, See WA, Loening SA, Williams RD: Urological laparoscopic surgery. J Urol 146:941–948, 1991
  51. Cantrell BB, DeKlerk DP, Eggleston JC, Boitnott JK, Walsh PC: Pathological factors that influence prognosis in Stage A prostatic cancer: the influence of extent versus grade. J Urol 125:516–520, 1981 | PubMed |
  52. Sheldon CA, Williams RD, Fraley EE: Incidental carcinoma of the prostate: A review of the literature and critical reappraisal of classification. J Urol 124:626, 1980 | PubMed | ChemPort |
  53. Epstein JI, Paul G, Eggleston JC, Walsh PC: Prognosis of untreated Stage A1 prostatic cancer: A study of 94 cases with extended follow-up. J Urol 136:837, 1986 | PubMed |
  54. Zincke H, Blute ML, Fallen MJ, Farrow GM: Radical prostatectomy for stage A adenocarcinoma of the prostate: Staging errors and their implications for treatment recommendations and disease outcome. J Urol 146:1053–1058, 1991
  55. Smith JA, Cho YH: Management of stage A prostate cancer. Urol Clin North Am 17:769, 1990
  56. Catalona WJ, Bigg SW: Nerve-sparing radical prostatectomy: Evaluation of results after 250 patients. J Urol 143:538, 1990 | PubMed | ChemPort |
  57. Smith PH: The case for no initial treatment of localized prostate cancer. Urol Clin North Am 17:827, 1990
  58. Mostofi FK: Grading of prostatic carcinoma: Cancer Chemother Reports 59:111, 1975
  59. Epstein JI, Berry SJ, Eggleston JC: Nuclear roundness factor: a predictor of progression in untreated Stage A2 prostate cancer. Cancer 54:1666, 1984
  60. Gleason DF: Classification of prostatic carcinomas. Cancer Chemother Reports 50:125, 1966
  61. Bagshaw MA, Cox RS, Ramback JE: Radiation therapy for localized prostate cancer. Urol Clin North Am 17:787, 1990
  62. Tribukait B, Ronstrum L, Esposti PL: Quantitative and qualitative aspects of flow DNA measurements related to the cytologic grade in prostatic carcinoma. Anat Quant Cytol 5:107, 1983
  63. DeVere White R, Deitch AD, Tomeshevsky P, Olsson CA: Flow cytometry in prostatic adenocarcinoma. World J Urol 1:55, 1983
  64. Stephenson RA, James BC, Gay H, Fair WR, Whitmore WF Jr, Melamed MR: Flow cytometry of prostate cancer: relationship of DNA content to survival. Cancer Res 47:2504–2507, 1987
  65. Winkler HZ, Rainwater LM, Myers RP, Farrow GM, Therneau TM, Zincke H, Lieber MM: Stage D1 prostatic adenocarcinoma: significance of nuclear DNA ploidy patterns studied by flow cytometry. Mayo Clin Proc 63:103–112, 1988 | PubMed | ISI | ChemPort |
  66. Lee SE, Currin SM, Paulson DF, Walther PJ: Flow cytometric determination of ploidy in prostatic adenocarcinoma: A comparison with seminal vesicle involvement and histopathological grading as a predictor of clinical recurrence. J Urol 140:769, 1988
  67. Ring KS, Karp FS, Olsson CA, O'Toole K, Bixon R, Benson MC: Flow cytometric analysis of adenocarcinoma of the prostate: the use of archival DNA analysis in conjunction with pathological grading to predict clinical outcome following radical retropubic prostatectomy. Prostate 17:155–164, 1990
  68. Fregevu O, Pontes JE, Levin HS, Bauer TW, Tubbs RR: DNA ploidy of adenocarcinoma of the prostate obtained from freshly processed specimens (abstract). J Urol 145:252A, 1991
  69. Whitmore WF, Hilaris B, Grabstald H: Retropubic implantation of iodine 125 in the treatment of prostate cancer. J Urol 108:918, 1972 | PubMed | ISI |
  70. Paulson DF, Uro-oncology Research Group: Radical surgery vs radiotherapy for stage A2 and stage B (T1-2 NoMo) adenocarcinoma of the prostate. J Urol 128:502, 1982
  71. Bagshaw MA, Cox RS, Ray GR: Status of radiation treatment of prostate cancer at Stanford University. NCI Monogr 7:47, 1988
  72. Jewett HJ: Significance of the palpable prostatic nodule. JAMA 160:838, 1956
  73. Culp OS: Radical prostatectomy: Its past, present and possible future. J Urol 98:618, 1968
  74. McGowan DG: Radiation therapy in the management of localized carcinoma of the prostate. Cancer 39:98, 1977
  75. Pilepich MV: Radiation Therapy Oncology Group studies in carcinoma of the prostate. NCI Monogr 7:61, 1988
  76. Bagshaw MA: Radiation therapy for cancer of the prostate, in Diagnosis and Management of Genitourinary Cancer, edited by Skinner DG, Lieskovsky G, Philadelphia, Saunders, 1988, pp 425–445
  77. Walsh PC, Lepor H, Eggleston JC: Radical prostatectomy with preservation of sexual function: Anatomic and pathologic considerations. Prostate 4:473, 1983 | PubMed | ISI | ChemPort |
  78. Peters CA, Walsh PC: Blood transfusion and anesthetic practices in radical retropubic prostatectomy. J Urol 134:81, 1985
  79. Catalona WJ: Patient selection for, results of and impact on tumor resection of potency-sparing radical prostatectomy. Urol Clin North Am 17:819, 1990 | PubMed | ChemPort |
  80. Schellhammer PF, el-Mahdi AM, Higgins EM, Schultheiss TE, Ladaga LE, Babb TJ: Prostate biopsy after definitive treatment by interstitial 125 iodine implant or external beam radiation therapy. J Urol 137:897–901, 1987 | PubMed | ChemPort |
  81. Kabalin JN, Hodge KK, McNeal JE, Freiha FS, Stamey TA: Identification of residual cancer in the prostate following radiation therapy: Role of transrectal ultrasound guided biopsy and prostate specific antigen. J Urol 142:326–331, 1989
  82. Scardino PT: The significance of biopsies after radiotherapy for prostatic cancer. Semin Urol 1:243, 1983
  83. Freiha FS, Bagshaw MA: Carcinoma of the prostate: results of post-irradiation biopsy. Prostate 5:19, 1984 | Article | PubMed | ChemPort |
  84. Ragde H, Blasko JC, Schumacher BS, Grimm PD, Cunningham DL, Sylvester J, Mate TP: Use of transrectal ultrasound in transperineal 125 iodine seeding for prostate cancer; methodology. J Endourol 3:209, 1989
  85. Donnelly BJ, Pedersen JE, Porter AT, McPhee MS: Iridium 192 brachytherapy in the treatment of cancer of the prostate. Urol Clin North Am 18:481, 1991
  86. Walsh PC, Jewett HJ: Radical surgery for prostate cancer. Cancer 45:1906, 1980
  87. Gibbons RP, Correa RJ Jr, Brannen GE, Weissman RM: Total prostatectomy for clinically localized prostatic cancer: long-term results. J Urol 141:564–566, 1989
  88. Russell KJ, Dunatov C, Haferman MD, Griffeth JT, Polissar L, Pelton J, Cole SB, Taylor EW, Weins LW, Koh WJ: Prostate specific antigen in the management of patients with localized adenocarcinoma of the prostate treated with radiation therapy. J Urol 146:1046–1052, 1991
  89. Pistenma DA, Bagshaw MA, Freiha FS: Extended field radiation therapy for prostatic adenocarcinoma: Status report of a limited prospective trial, in Cancer of the Genitourinary Tract, edited by Johnson DE, Samuels ML, New York, Raven, 1979, p 229
  90. Bagshaw MA: Perspectives in the radiation treatment of prostatic cancer: History and current focus, in Prostatic Cancer, edited by Murphy G, Boston, Little, Brown, 1979
  91. Zincke H, Fleming TR, Furlow WL, Myers RP, Utz DC: Radical retropubic prostatectomy and pelvic lymphadenopathy for high-stage cancer of the prostate. Cancer 47:1901–1910, 1981
  92. Zinche H, Utz DC, Taylor WF: Bilateral pelvic lymphadenectomy and radical prostatectomy for clinical stage C prostatic cancer: Role of adjuvant treatment for residual cancer and in disease progression. J Urol 135:1199, 1986
  93. DeKernion JB, Neuwirth H, Stein A, Dorey F, Stenzl A, Hannah J, Blyth B: Prognosis of patients with stage D1 prostate carcinoma following radical prostatectomy with and without early endocrine therapy. J Urol 144:700–703, 1990 | PubMed | ChemPort |
  94. Fallon B, Williams RD: Current options in the management of clinical stage C prostatic carcinoma. Urol Clin North Am 17:853, 1990
  95. Austenfed MS, Davis BE: New concepts in the treatment of stage D1 adenocarcinoma of the prostate. Urol Clin N Am 17:867, 1990
  96. Walsh PC: Physiologic basis for hormonal therapy in carcinoma of the prostate. Urol Clin North Am 2:125, 1975
  97. Veterans Administration Cooperative Urological Research Group: Carcinoma of the prostate: Treatment comparisons. J Urol 98:516, 1967
  98. Byar DP, Corle DK: Hormone therapy for prostate cancer: results of the VACURG studies. NCI Monogr 7:165, 1988
  99. Shearer RJ, Hendry WF, Sommerville IF, Fergusson JD: Plasma testosterone: An accurate monitor of hormonal treatment in prostatic cancer. Br J Urol 45:668, 1973 | PubMed | ChemPort |
  100. Leuprolide Study Group: Leuprolide vs. diethylstilbestrol for metastatic prostate cancer. N Engl J Med 311:1281, 1984
  101. Kuhn JM, Billebaud T, Navratil H, Moulonguet A, Fiet J, Grise P, Louis JF, Costa P, Husson JM, Dahan R: Prevention of the transient adverse effects of a gonadotropin-releasing hormone analogue (buserelin) in metastatic prostatic carcinoma by administration of an antiandrogen (nilutamide). N Engl J Med 321:413–418, 1989
  102. Labrie F, Dupont A, Belanger A, Cusan L, Lacourciere Y, Monfette G, Laberge JG, Emond JP, Fazekas AT, Raynaud JP, Husson JM: New hormonal therapy in prostatic carcinoma: combined treatment with an LHRH agonist and an antiandrogen. Clin Invest Med 5:267–275, 1982 | PubMed | ISI | ChemPort |
  103. Crawford ED, Eisenberger MA, McLeod DG, Spaulding JT, Benson R, Dorr FA, Blumenstein BA, Davis MA, Goodman PJ: A controlled trial of leuprolide with and without flutamide in prostatic carcinoma. N Engl J Med 321:419–424, 1989 | PubMed | ISI | ChemPort |
  104. Trachtenberg J, Beland G, Elhilali MM, Fradet Y, Laroche B, Ramsey EW, Venner PN: A randomized trial of total androgen ablation vs orchiectomy in patients with metastatic prostate cancer (abstract). J Urol 141:347A, 1989
  105. DeVoogt HJ, Klijn JG, Studer U, Schroeder FG, Sylvester R, de Pauw M: The combination of LHRH against buserilin with cyproterone acetate for 2 weeks initially vs continuously vs orchiectomy in the treatment of advanced prostate cancer. Results of EORTC trial 30843 (abstract). J Urol 145:290A, 1991
  106. Gillat DA, Chadwick D, Gingell JC, O'Boyle P, Fellows G, Peeling B: A randomized control trial of the LHRH analogue zoladex vs cyproterone acetate vs a combination of the two (abstract). J Urol 145:292A, 1991
  107. Janknegt RA, del Moral PF, Abbou C, Bracken B, Bartioletti R, Bernstein-Hann L, Brisset JM, Calais de Silva F, Chisholm G, Crawford E, Frick J, Goedhals L, Knonagel H, Venne P, Debruyne FMJ: Efficiency and tolerance of a total androgen blockade with anandron and orchiectomy: a double blind placebo controlled multicenter study (abstract). J Urol 145:425A, 1991
  108. Eisenberger MA, Abrams JS: Chemotherapy for prostatic carcinoma. Semin Urol 6:303, 1988
  109. Linehan WM, Cooper M, LaRocca R, Walther GH, Weiss C, Stein C, Steinberg SM, Cassidy J, Uhrich M, Myers CM: Suramin therapy of patients with advanced hormone refractory prostate carcinoma (abstract). J Urol 145:317A, 1991
  110. Crawford ED, Schutz M, Clejan S, Drago J, Resnick MI, Chodak GW, Gomella LG, Austenfeld M, Stone NN, Miles BJ: The effect of digital rectal examination on prostate specific antigen (abstract). J Urol 145:398A, 1991
  111. Parlow AL: Advanced cancer of the prostate: a consideration of radical prostatectomy in selected cases. NY State J Med 383–387, 1945
  112. Krain LS: Some epidemiologic variables in prostatic carcinoma in California. Prev Med 3:154–159, 1974 | PubMed | ISI | ChemPort |
  113. Ross RK, Deapen DM, Casagrande FT, Paganini-Hill A, Henderson BE: A cohort study of mortality from cancer of the prostate in Catholic priests. Br J Cancer 43:233–255, 1981 | PubMed | ISI | ChemPort |

Extra navigation

.
ADVERTISEMENT